Competitor Analysis: Insulin
Product description
The Competitive Intelligence Report Insulin as of January 2011 provides a competitor analysis in the development pipeline of novel insulin-based products for treatment of type 1 and 2 diabetes.
Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of current active projects in research and development of novel insulin-based products. In addition, the report lists company-specific product portfolios and R&D pipelines of insulin, insulin analogs and new delivery forms of insulin on the market or in R&D. Competitor projects are listed in a tabular format providing information on:
Drug Codes,
Target / Mechanism of Action,
Class of Compound,
Company,
Product category,
Indication,
R&D Stage and
additional comments with a hyperlink leading to the source of information.
Index
Rec Human Insulin for Injection (2nd Generation)
Biosimilar Rec Human Insulin for Injection (2nd Generation) in Regulated Markets
Rhu Insulin (2nd Generation) in Off-Patent Countries
China
Russia
India
Others
Modern Insulin Analogs (3rd Generation) for Injection
Modern Insulin Analogs (3rd Generation) in Less-Regulated Markets
Tailored and Novel Insulin Analogs (4th Generation) for Injection
Human Insulin with Drug Delivery for Injection
Other Long-Acting Insulin for Injection
Transgenic Human Insulin for Injection
Insulin/GLP-1 Combination Products
Inhaled Insulin
Oral Insulin
Transdermal Insulin
Others
Corporate Insulin Product Portfolio and R&D Pipelines:
Access Pharmaceuticals
Altea Therapeutics
Apricus Biosciences
Ascendis Pharma
Axxo
Bio Sidus
Biocon
Bayer Healthcare
Bayer Schering Pharma
Biodel
Biotek
Bioton
Boehringer Ingelheim
ConjuChem
Coremed
Diasome Pharmaceuticals
Eli Lilly
Emisphere Technologies
Flamel Technologies
Fosun Pharma
Gan & Lee Pharmaceutical Co.
Generex Biotechnology
Halozyme Therapeutics
JCOM Co Ltd
Laboratorios Cryopharma
LFB
Lipoxen
MannKind
Merck BioManufacturing Network
Merrion Pharmaceuticals
Midatech Group
MonoSol Rx
Novo Nordisk
Oramed Pharmaceuticals
Pfizer
PharmaIN
Pharmstandard
Phosphagenics
Proxima Concepts
Sanofi-Aventis
SciGen
SemBioSys Genetics
Shanghai Biolaxy
Shanghai Dongbao Biopharmaceutical Co.
Shemyakin-Ovchinnikov Institute of Bioorganic ChemistryShenzhen Kexing Biotech
Shreya Life Sciences
Tonghua Dongbao Pharmaceutical
Transgene Biotek
USV Ltd
Wanbang Biopharma
Wockhardt
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
The Competitive Intelligence Report Insulin as of January 2011 provides a competitor analysis in the development pipeline of novel insulin-based products for treatment of type 1 and 2 diabetes.
Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of current active projects in research and development of novel insulin-based products. In addition, the report lists company-specific product portfolios and R&D pipelines of insulin, insulin analogs and new delivery forms of insulin on the market or in R&D. Competitor projects are listed in a tabular format providing information on:
Drug Codes,
Target / Mechanism of Action,
Class of Compound,
Company,
Product category,
Indication,
R&D Stage and
additional comments with a hyperlink leading to the source of information.
Index
Rec Human Insulin for Injection (2nd Generation)
Biosimilar Rec Human Insulin for Injection (2nd Generation) in Regulated Markets
Rhu Insulin (2nd Generation) in Off-Patent Countries
China
Russia
India
Others
Modern Insulin Analogs (3rd Generation) for Injection
Modern Insulin Analogs (3rd Generation) in Less-Regulated Markets
Tailored and Novel Insulin Analogs (4th Generation) for Injection
Human Insulin with Drug Delivery for Injection
Other Long-Acting Insulin for Injection
Transgenic Human Insulin for Injection
Insulin/GLP-1 Combination Products
Inhaled Insulin
Oral Insulin
Transdermal Insulin
Others
Corporate Insulin Product Portfolio and R&D Pipelines:
Access Pharmaceuticals
Altea Therapeutics
Apricus Biosciences
Ascendis Pharma
Axxo
Bio Sidus
Biocon
Bayer Healthcare
Bayer Schering Pharma
Biodel
Biotek
Bioton
Boehringer Ingelheim
ConjuChem
Coremed
Diasome Pharmaceuticals
Eli Lilly
Emisphere Technologies
Flamel Technologies
Fosun Pharma
Gan & Lee Pharmaceutical Co.
Generex Biotechnology
Halozyme Therapeutics
JCOM Co Ltd
Laboratorios Cryopharma
LFB
Lipoxen
MannKind
Merck BioManufacturing Network
Merrion Pharmaceuticals
Midatech Group
MonoSol Rx
Novo Nordisk
Oramed Pharmaceuticals
Pfizer
PharmaIN
Pharmstandard
Phosphagenics
Proxima Concepts
Sanofi-Aventis
SciGen
SemBioSys Genetics
Shanghai Biolaxy
Shanghai Dongbao Biopharmaceutical Co.
Shemyakin-Ovchinnikov Institute of Bioorganic ChemistryShenzhen Kexing Biotech
Shreya Life Sciences
Tonghua Dongbao Pharmaceutical
Transgene Biotek
USV Ltd
Wanbang Biopharma
Wockhardt
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
